Skip to content

Role of 18F-FDG PET/CT in the Evaluation of Cavernous Sinus Syndrome: a Pilot Study

Role of 18F-FDG PET/CT in the Evaluation of Cavernous Sinus Syndrome: a Pilot Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06721130
Enrollment
54
Registered
2024-12-06
Start date
2022-07-01
Completion date
2024-06-30
Last updated
2024-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cavernous Sinus Lesions, Cavernous Sinus Meningioma, Cavernous Sinus Syndrome

Keywords

Cavernous Sinus Syndromes, Ophthalmoplegia, Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Cavernous Sinus

Brief summary

Cavernous sinus syndrome (CSS) can be caused by a wide range of inflammatory, malignant, benign, vascular and miscellaneous disorders. Even after modern advances, reaching the final etiological diagnosis remains a challenge in CSS. This study is planned to determine the role and incremental value of 18F-FDG PET/CT in characterising different cavernous sinus pathologies based on their metabolic activity and detecting extracranial involvement.

Interventions

DIAGNOSTIC_TESTFDG radiotracer

Pilot study evaluating the role of FDG PET/CT in Cavernous sinus syndrome

Sponsors

Post Graduate Institute of Medical Education and Research, Chandigarh
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patients with age greater than or equal to 18 years, 2. with newly diagnosed CSS, 3. lesion seen on MRI in the CS, and 4. willing to give written informed consent.

Exclusion criteria

1. Pregnant and lactating patients 2. Patients already being treated (including steroids)

Design outcomes

Primary

MeasureTime frameDescription
SUVmax of the cavernous sinus lesions on FDG PET/CTFrom enrollment to the establishment of final diagnosis upto a period of three monthsStandardized uptake value (SUV) will be calculated by drawing region of interest (ROI) in the cavernous sinus region both on the whole body and the dedicated brain image, while carefully excluding normal brain activity. If lesions in the bilateral cavernous sinuses will be present, SUVmax of both the lesions will be noted.
Number of patients with extracranial sites of involvement on FDG PET/CTFrom enrollment to the establishment of final diagnosis upto 3 months

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026